- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Dr Brandon Shank: Pharmacist Education on Biosimilars
Brandon Shank, PharmD, MPH, BCOP, Clinical Pharmacy Specialist, discusses the importance of pharmacist education on biosimilar treatments.
Transcript (Slightly Edited):
Education is paramount with the implementation of biosimilars for pharmacists. Currently, there is an education gap because the FDA is finalizing the naming documents and how these drugs will be approved and make it to market. As more drugs become available, this gap will close, and pharmacists will become more used to seeing these in practice and utilizing these agents. They will become more familiar with the packaging differences, the naming, and the indications of use. So, they will be able to dispense these products with confidence.
Newsletter
Where clinical, regulatory, and economic perspectives converge—sign up for Center for Biosimilars® emails to get expert insights on emerging treatment paradigms, biosimilar policy, and real-world outcomes that shape patient care.
